PROBLEM TO BE SOLVED: To provide a medicinal composition for treating disorders of the central nervous system associated with 5-HT1A receptor subtype, especially treatment-resistant schizophrenia, treatment-resistant schizophrenia accompanying cognitive disorder, inveterate schizophrenia, inveterate schizophrenia accompanying cognitive disorder, chronic schizophrenia, or chronic schizophrenia accompanying cognitive disorder.SOLUTION: The medicinal composition contains a therapeutically effective amount of a carbostyryl compound of formula (1) (wherein, the carbon-carbon bond between the 3- and 4-positions of a carbostyryl skeleton is a single bond or a double bond), and a pharmaceutically acceptable salt or solvate thereof.COPYRIGHT: (C)2008,JPO&INPIT【課題】5-HT1A受容体サブタイプに関連した中枢神経系の障害、特に治療抵抗性精神分裂病、認知障害を伴う治療抵抗性精神分裂病、難治性精神分裂病、認知障害を伴う難治性精神分裂病、慢性精神分裂病、又は認知障害を伴う慢性精神分裂病を治療するための医薬組成物。【解決手段】式(1):(カルボスチリル骨格の3位及び4位の間の炭素-炭素結合は、単結合又は二重結合である);のカルボスチリル化合物、及び医薬として許容されるその塩又は溶媒和物の治療有効量を含む医薬組成物。【選択図】なし
